BREAKING
Tempest Therapeutics, Inc. (TPST) Reports FY2025 Earnings 3 minutes ago Scienture Holdings Inc (MEDS) Reports FY2025 Earnings 7 minutes ago Avis Budget Group, Inc. (CAR) Drops 1.6% to $146 36 minutes ago PDS Biotechnology Corporation (PDSB) FY 2025 Earnings Recap 55 minutes ago Unicycive Therapeutics, Inc. (UNCY) Reports FY2025 Earnings 1 hour ago USA Rare Earth, Inc. (USAR) Reports Q4 Earnings 1 hour ago Bicara Therapeutics 2025 Financial Update 1 hour ago PDS Biotechnology Corporation (PDSB) Reports FY2025 Earnings 2 hours ago Neumora Therapeutics 2025 Financial Update 2 hours ago Americas Gold and Silver Corporation (USAS) Misses FY2025 EPS Estimates by 425.0% 2 hours ago Tempest Therapeutics, Inc. (TPST) Reports FY2025 Earnings 3 minutes ago Scienture Holdings Inc (MEDS) Reports FY2025 Earnings 7 minutes ago Avis Budget Group, Inc. (CAR) Drops 1.6% to $146 36 minutes ago PDS Biotechnology Corporation (PDSB) FY 2025 Earnings Recap 55 minutes ago Unicycive Therapeutics, Inc. (UNCY) Reports FY2025 Earnings 1 hour ago USA Rare Earth, Inc. (USAR) Reports Q4 Earnings 1 hour ago Bicara Therapeutics 2025 Financial Update 1 hour ago PDS Biotechnology Corporation (PDSB) Reports FY2025 Earnings 2 hours ago Neumora Therapeutics 2025 Financial Update 2 hours ago Americas Gold and Silver Corporation (USAS) Misses FY2025 EPS Estimates by 425.0% 2 hours ago
ADVERTISEMENT
Breaking News

Scienture Holdings Inc (MEDS) Reports FY2025 Earnings

Scienture Holdings Inc (MEDS) posted Q4 2025 basic and diluted EPS of -$2.70.

March 30, 2026 1 min read

Scienture Holdings Inc (MEDS) posted Q4 2025 basic and diluted EPS of -$2.70.

MEDS|EPS -$2.70|Rev $431,609|Net Loss $41.5M

Scienture Holdings Inc (MEDS) posted FY 2025 basic and diluted EPS of -$2.70. Revenue totaled $431,609 for the year. Revenue of $431,609 was up 216.0% year-over-year.

Bottom line showed a net loss of $41.5M.

This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.

ADVERTISEMENT